HOME >> MEDICINE >> NEWS
Clinical data suggest potential versatility of ALIMTA-based regimens in lung cancer

CHICAGO, June 2, 2007 -- ALIMTA (pemetrexed for injection) showed additional utility in the treatment of the most diagnosed type of cancer , according to data presented today at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO). Results from a Phase III study suggest that a first-line ALIMTA-based regimen may deliver less toxicity than a commonly used therapy in advanced non-small cell lung cancer (NSCLC). ALIMTA is manufactured and marketed by Eli Lilly and Company.

A prospective, randomized, multicenter Phase III study was conducted to compare ALIMTA plus carboplatin with the commonly used regimen of GEMZAR (gemcitabine HC1 for injection) plus carboplatin (ASCO Abstract # 7517 ). The study, conducted by the Norwegian Lung Cancer Group, enrolled 446 chemonave patients with either stage IIIB or IV NSCLC. The primary purpose of the study was to evaluate if the ALIMTA-carboplatin combination provided increased quality-of-life benefits while offering comparable survival data. As such, the primary endpoint was quality of life (defined in the study as nausea/vomiting; dyspnea or a difficulty in breathing, and; fatigue) and the secondary endpoint was overall survival.

Thus far, 384 patients have been analyzed for toxicity and there were fewer patients in the ALIMTA arm who experienced Grade 3/4 thrombocytopenia or a low platelet level (48 vs. 107, p<.001); leukopenia or a lowering of leukocyte white blood cells (44 vs. 89, p<.001), and; granulocytopenia or a lowering of granulocyte white blood cells (78 vs. 98, p=.02). More patients in the GEMZAR arm received transfusion of platelets (5 vs. 19, p=.02). At this point, no difference in survival has been observed.

The patients in this study received a comparable quality-of-life benefit whether they received ALIMTA and carboplatin or GEMZAR and carboplatin, said Bjrn Henning Grnberg, M.D. of St. Olavs University Hospital in Norway and the studys principal investigat
'"/>

Contact: Neil Hochman
n.hochman@cprworldwideusa.com
212-453-2067
CPR Worldwide
2-Jun-2007


Page: 1 2 3

Related medicine news :

1. Susan G. Komen for the Cure and American Society of Clinical Oncology partner in national initiative
2. Clinical review -- A psychological approach to the management of irritable bowel syndrome
3. NHLBI Asthma Clinical Research Networks and ALA ACRC Network to present at ATS 2007
4. Clinical trial data for Perforomist Inhalation Solution presented at International ATS Conference
5. Clinical guidelines for blood conservation during cardiac procedures developed
6. Clinical trial data for Perforomist Inhalation Solution to be presented at ATS on May 20, 2007
7. Clinical trial coordinators need more financial conflict-of-interest training
8. Clinical studies evaluate potential treatments for mouth ulcers
9. NIH names Clinical Trial Units for the Microbicide Trials Network
10. Clinical Trials Units selected for newly restructured HIV/AIDS research networks
11. Study in recent issue of Clinical Pediatrics helps pediatricians to understand discipline practices

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/19/2019)... ... 19, 2019 , ... Marking a key milestone in the ... on Wednesday will lift into place the final steel beam at AHN ... year. , The nearly 79,000-square-foot facility – located at 6321 Route 30, Greensburg, ...
(Date:2/19/2019)... HILLS, Calif. (PRWEB) , ... February 19, 2019 ... ... Wachler Vision Institute, Brian Boxer Wachler, MD, has launched the first ever supplement ... that can lead to severe to severe vision loss. The supplement, KC Defense, ...
(Date:2/19/2019)... ... February 19, 2019 , ... ... with town halls across the country , A partnership between Liberty University and ... crisis, continues with its next town hall event on Tuesday, February 19, at ...
(Date:2/19/2019)... JACKSONVILLE, Fla. (PRWEB) , ... February 19, 2019 ... ... professors say yes! , “Nova Filtration is based in The Villages FL proudly ... success in our new franchised Territory in the greater Jacksonville area selling and ...
(Date:2/19/2019)... ... February 19, 2019 , ... Dr. Lombardi is ... Oncology Institute of Hope and Innovation. , Dr. Lombardi completed his undergraduate in ... received his medical degree from the University of Rochester School of Medicine. He ...
Breaking Medicine News(10 mins):
(Date:2/16/2019)... ... February 15, 2019 , ... ... Allison Marlow of Perio-Implant Care are urging patients to take their oral health ... cancers, diabetes, Alzheimer's and dementia, and risk of pre-term birth, there is plenty ...
(Date:2/16/2019)... ... 15, 2019 , ... Dr. Lucas Bryant, board-certified Face expert ... Haute Beauty Network, well known for their exclusivity, and luxurious lifestyle, is privileged ... newest addition to the Haute Living partnership. , Haute Beauty offers a prominent ...
(Date:2/14/2019)... Colo. (PRWEB) , ... February 14, 2019 , ... ... Month , Lewis and Clark College Emeritus Professor of Education Gregory A. Smith ... They discuss the emergence of Brand Ambassador programs, a new phenomenon in the ...
Breaking Medicine Technology:
Cached News: